Patents Issued in April 21, 2016
  • Publication number: 20160106669
    Abstract: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 21, 2016
    Inventors: Robert O. Cook, Stephen B. Shrewsbury, Nabih N. Ramadan, Thomas A. Armer
  • Publication number: 20160106670
    Abstract: The present invention provides a process for the production of an oil in water emulsion comprising the step of a) introducing an oil phase into a mixing device by applying a positive pressure in the oil phase containing tank.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Inventors: Vinciane DE CUPERE, Vincent MANCUSO
  • Publication number: 20160106671
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: December 16, 2015
    Publication date: April 21, 2016
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Publication number: 20160106672
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
  • Publication number: 20160106673
    Abstract: The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicant: BIOCOMPATIBLES UK LIMITED
    Inventors: Andrew Lennard LEWIS, Giuseppe BATTAGLIA, Irene CANTON, Peter William STRATFORD
  • Publication number: 20160106674
    Abstract: Collagen powder in which at least 99.5% of the particles have a maximum size of 80 microns 25% to 45% by volume of the particles have a size of more than 30 microns and 35% to 50% by volume of the particles have a size in the range of 20 to 70 microns.
    Type: Application
    Filed: May 15, 2013
    Publication date: April 21, 2016
    Inventor: Juan Francisco SCALESCIANI
  • Publication number: 20160106675
    Abstract: A composition having a mixture of discreet particles, each particle comprising an active substance and a coating material, the active substance being at least partially coated with the coating material. The mixture of discreet particles includes a first batch of first particles, the first particles of the first batch having a first average weight % ratio of the active substance to the coating material; and a second batch of second particles, the second particles of the second batch having a second average weight % ratio of the active substance to the coating material, the second average weight ratio being different from the first average weight ratio.
    Type: Application
    Filed: June 10, 2015
    Publication date: April 21, 2016
    Inventors: Joseph J. BURCH, Patrick A. JOBE
  • Publication number: 20160106676
    Abstract: The present application relates to an aqueous method for the preparation of microgel particles using a stimuli-responsive prepolymer
    Type: Application
    Filed: October 19, 2015
    Publication date: April 21, 2016
    Inventors: Todd Hoare, Daryl Sivakumaran, Madeline Simpson, Eva Mueller
  • Publication number: 20160106677
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and metformin XR (extended release), processes for the preparation thereof, and their use to treat certain diseases.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Inventors: Georg BOECK, Venkata VOLETI, Tracy WILLIAMSON
  • Publication number: 20160106678
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicants: POZEN INC., HORIZON PHARMA USA, INC.
    Inventors: Brian AULT, Everardus ORLEMANS, John R. PLACHETKA, Mark SOSTEK
  • Publication number: 20160106679
    Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I in the form of its free base or pharmaceutically acceptable salts of compound I.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 21, 2016
    Inventors: Johannes Raneburger, Ludwig Englmeier, Andreas Krekeler, Michael Sedlmayr
  • Publication number: 20160106680
    Abstract: The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compound selected from the group consisting of: polysaccharides, sugars, sugar derived alcohols, starches, starch derivatives, cellulose derivatives, Carrageenan, pectin, sodium alginate, gellan gum, xanthan gum, poloxamer, Carbopol®, PolyOx®, povidone, hydroxypropyl methylcellulose (HPMC), hypermellose, and combinations thereof; at least one disintegrant and optionally at least one surfactant, wherein said formulation exhibit properties related to deterring the abuse, via injection or nasal inhalation when being tampered and exposed to aqueous, alcoholic, acidic and basic media.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 21, 2016
    Applicant: Pharmascience Inc.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Publication number: 20160106681
    Abstract: A vegetarian pore-sealing capsule is provided. The pore-sealing capsule may release active substances in a gastrointestinal tract, including stomach, duodenum, jejunum, ileum and colon, under control. The pore-sealing capsule includes a capsule shell having one or more pores and a pore-sealing material for sealing at least one of the pores. When the pore-sealing capsule is located at a destination inside the gastrointestinal tract, the pore-sealing material will leave the pores.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 21, 2016
    Inventor: Chao-Hsiang Chang
  • Publication number: 20160106682
    Abstract: A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Inventors: EmadEldin M. HASSAN, Aqeel A. FATMI, Nachiappan CHIDAMBARAM
  • Publication number: 20160106683
    Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Applicant: ADARE PHARMACEUTICALS, INC.
    Inventor: Gopi M. Venkatesh
  • Publication number: 20160106684
    Abstract: This disclosure relates to nanoparticle drug delivery systems composed of casein (CN) coated nanoparticles, e.g., iron oxide nanoparticles coated with an inner layer and an out layer comprising the milk protein casein. In certain embodiments, drug molecules are incorporated into an inner polymeric layer coating the nanoparticles, which are subsequently coated with a casein containing outer layer, i.e., a layer-by-layer (LBL) construction. Oral administration of these casein coated nanoparticles are contemplated as experiments indicated sufficiently stability in conditions that simulate the conditions of the gut. Drugs that were loaded into the nanoparticle systems were released when the casein outer layer was gradually degraded in the presence of an intestinal protease meant to simulate conditions of the intestine.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 21, 2016
    Applicant: EMORY UNIVERSITY
    Inventors: Hui Mao, Jing Huang
  • Publication number: 20160106685
    Abstract: This invention reports ciprofloxacin (CIP)-encapsulated polymeric nanoparticles and its antibacterial potential with a variety of gram positive and gram negative pathogenic bacteria. CIP-encapsulated nanoparticles of diethylaminoethyl cellulose (DEA-EC) are prepared by the multiple emulsion solvent evaporation method. CIP-encapsulated nanoparticles showed superior effectiveness to inhibit the growth of bacteria in-vitro.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 21, 2016
    Inventors: Muhammad Akhyar Farrukh, Muhammad Rehan Gul, Muhammad Khaleeq-ur- Rahman
  • Publication number: 20160106686
    Abstract: A novel backing construction for a transdermal drug delivery system is disclosed. In particular, the invention relates to a system and method for labeling a transdermal drug delivery system, wherein the backing layer contains a writable medium capable of inkless printing.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicant: ALZA Corporation
    Inventor: Jay Douglas Audett
  • Publication number: 20160106687
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Application
    Filed: May 26, 2015
    Publication date: April 21, 2016
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Publication number: 20160106688
    Abstract: An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Thomas CHRISTOPH, Sabine Karine Katrien INGHELBRECHT, Roger Carolus Augusta EMBRECHTS, Ulrich REINHOLD, Marc SCHILLER, Eva WULSTEN, Petra BLOMS-FUNKE, Klaus SCHIENE, Ulrich FEIL
  • USE
    Publication number: 20160106689
    Abstract: The present invention relates to compositions comprising cysteamine or a derivative thereof for use in treating infections caused by yeasts or moulds.
    Type: Application
    Filed: September 22, 2015
    Publication date: April 21, 2016
    Applicant: NOVABIOTICS LIMITED
    Inventor: Deborah O'NEIL
  • Publication number: 20160106690
    Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 21, 2016
    Applicant: API GENESIS, LLC
    Inventors: Daniel BUCKS, Philip J. BIRBARA
  • Publication number: 20160106691
    Abstract: This invention relates to chemistry and biochemistry applied to the field of medicine and is referred to a new method of prevention and therapeutic treatment of conformational diseases (CD), in particular to amyloid origin diseases by administrating an effective amount of one or more compounds, salts, prodrugs or solvates, which are considered herein as chemical chaperonins, of Formula I, Where: R1: -alkylenyl-C(O)NH-alkylenyl-R3, -alkylenyl-C(O)O—R4; R3: —COOH, —OH, —SH, —NH2, —NH-alkyl-, —NH-dithiocarbamate-alkyl, —N-alkyl-dithiocarbamate alkaline earth metal salts. R4: succinimidyl group. R2: —H, -alkyl; wherein the term “alkyl” is characterized by a linear or branched aliphatic chain, hydrogen and saturated carbon atoms, comprising a methyl, ethyl, n-propyl, iso-propyl, n-butyl or iso-butyl groups. Wherein, the term “alkylenyl” refers to a divalent analog of a linear or branched alkyl group, preferably ethylenyl (—CH2CH2—) or butylenyl (—CH2CH2CH2CH2—) radicals.
    Type: Application
    Filed: December 30, 2013
    Publication date: April 21, 2016
    Inventors: MARQUIZA SABLON CARRAZANA, Chrislayne RODRIGUEZ-TANTY, Myriam Marlene ALTAMIRANO BUSTAMANTE, Fernand Vedrenne GUTIERREZ, Suchitil RIVERA MARRERO, Isaac Gomez FERNANDEZ, Rosa Maria LOPEZ BARROSO, Lina Andrea RIVILLAS ACEVEDOº, Reyna LARA MARTINEZ, Rafaela PEREZ PERERA, Alberto Guadalupe BENCOMO MARTINEZ, Maria Guadalupe DOMINGUEZ MACOUZET, Luis Felipe JIMENEZ GARCIA, Massiel DIAZ MIRANDA, Andreade Julio MORAN, Pedro VALDES SOSA, Alejandro PERERA PINADO, Anais PRATS CAPOTE, Sergio Agustin ISLAS ANDRADE
  • Publication number: 20160106692
    Abstract: Embodiments disclosed herein relate to certain compositions including X-ray contrast media compounds and/or certain tri-iodinated phenyl compounds and methods of using the same for preventing or treating filovirus infections.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 21, 2016
    Inventors: Elliott C. Lasser, Jesus Ernesto Villafranca, Erik S. Viirre
  • Publication number: 20160106693
    Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 21, 2016
    Inventors: Yehezkel BEN-ARI, Nathalie DEHORTER, Philippe DAMIER, Constance HAMMOND
  • Publication number: 20160106694
    Abstract: The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Inventors: Michael J. Roberts, Simon Pedder
  • Publication number: 20160106695
    Abstract: The present invention relates to the field of weight management and obesity. It concerns petroselinic acid or a combination of active ingredients including at least petroselinic acid and at least one compound chosen from zinc, taurine, one of the salts of same, lycopene and the mixtures thereof, and preferably at least taurine or zinc gluconate and, more preferably still, at least taurine and zinc gluconate, as a drug for oral administration or as a functional food intended to promote weight loss and/or weight maintenance in a human being and/or animal, or indeed intended to fight obesity.
    Type: Application
    Filed: May 6, 2014
    Publication date: April 21, 2016
    Inventors: Yann MAHE, Carole BRU, Audrey GUENICHE
  • Publication number: 20160106696
    Abstract: The present invention relates to cancer therapy by administering a specific dietary composition. Especially the invention relates to a pharmaceutical, medical food or dietary supplement composition comprising the combination of the following three active ingredients: hydroxytyrosol, fish oil EPA/DHA and curcumin. The pharmaceutical composition is useful in the treatment or prevention of cancer, especially breast cancer.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 21, 2016
    Inventors: Carlos María Peña Díaz, Guillerm Muñoz Fernández, Michael Morse
  • Publication number: 20160106697
    Abstract: Described herein are methods for making retinoids. Also described herein are retinoids and methods of use thereof.
    Type: Application
    Filed: September 21, 2015
    Publication date: April 21, 2016
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Wayne J. Brouillette, Donald D. Muccio, Venkatram Reddy Atigadda, John M. Ruppert, Susan M. Lobo Ruppert
  • Publication number: 20160106698
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: January 18, 2013
    Publication date: April 21, 2016
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20160106699
    Abstract: Oral pharmaceutical composition containing, in the same pharmaceutical form, effective amounts of a HMG-CoA reductase inhibitor derivative and of PPAR?, especially fenofibrate. Also described is the use of some inactive ingredients which allow to improve the dissolution and/or bioavailability of the drugs from the said composition.
    Type: Application
    Filed: April 17, 2009
    Publication date: April 21, 2016
    Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier
  • Publication number: 20160106700
    Abstract: A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 21, 2016
    Inventors: Todd W. Chappell, Keith A. Johnson
  • Publication number: 20160106701
    Abstract: Provided is a novel method for preventing and/or treating hairy wart disease which is a hoof and leg disease of ungulates. The method is carried out by administering an isothiocyanic acid ester such as allyl isothiocyanate to a hoof of an ungulate. Examples of ungulates targeted for application of the present invention include cows such as dairy cows as well as sheep, pigs and horses.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 21, 2016
    Applicants: Mitsubishi-Kagaku Foods Corporation, Incorporated National University Iwate University
    Inventors: Keiji OKADA, Yasushi SEKIYAMA
  • Publication number: 20160106702
    Abstract: The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic-floor disorders by administering a SARM compound of the invention.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Inventors: Ramesh NARAYANAN, Jeffrey G. Hesselberg, Mary Ann Johnston, Robert H. Getzenberg
  • Publication number: 20160106703
    Abstract: The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Application
    Filed: May 21, 2015
    Publication date: April 21, 2016
    Inventor: James E. Vath
  • Publication number: 20160106704
    Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and blister packs and kits comprising cromolyn are described.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 21, 2016
    Applicant: AZTHERAPIES, INC
    Inventors: DAVID R. ELMALEH, ALEX FRANZUSOFF
  • Publication number: 20160106705
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations.
    Type: Application
    Filed: October 21, 2015
    Publication date: April 21, 2016
    Inventors: Tony Verzura, Earnie Blackmon
  • Publication number: 20160106706
    Abstract: There is provided a delivery vehicle comprising an anti-cancer agent together with a conjugate of a delivery agent containing a free aldehyde and a flavonoid, having the delivery agent conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. The resulting delivery vehicles may be used to deliver an anti-cancer agent to a cell.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Applicant: Agency for Science, Technology and Research
    Inventors: Jackie Y. Ying, Joo Eun Chung, Motoichi Kurisawa
  • Publication number: 20160106707
    Abstract: The invention relates to a process for producing an aqueous gel comprising hyaluronic acid, vitamin C, and a stabilizing agent selected from the metabisulfites. According to the invention, such a process comprises the steps of a) preparing a mixture comprising crosslinked or non-crosslinked hyaluronic acid and/or a salt thereof with a molar mass of between 1000 Da and 10 MDa, from 0.1 to 20.0% by weight of vitamin C in its acid form, or its equivalent in ascorbate derived from a vitamin C salt, from 0.01 to 1.00% by weight of a stabilizing agent selected from the metabisulfites, and an aqueous solution added so that the hyaluronic acid content is between 0.01 and 100 mg/ml, so as to form a hydrogel, and b) degassing the mixture before the hydrogel being formed is completely swollen.
    Type: Application
    Filed: April 23, 2014
    Publication date: April 21, 2016
    Inventors: Alfred MARCHAL, Jerome CABOU, Damien LACROIX, Jacques DUBOIS
  • Publication number: 20160106708
    Abstract: The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Inventors: María Yolanda De Diego Otero, Lucia María Pérez Costillas, Ignacio Del Arco Herrera
  • Publication number: 20160106709
    Abstract: Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NF?B-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K.
    Type: Application
    Filed: December 31, 2015
    Publication date: April 21, 2016
    Inventors: Tetyana V. Masyuk, Nicholas F. LaRusso, Thomas M. Miller
  • Publication number: 20160106710
    Abstract: The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.
    Type: Application
    Filed: April 29, 2014
    Publication date: April 21, 2016
    Applicant: The Johns Hopkins University
    Inventors: Zhaoli Sun, George Melville Williams, Qing Lin
  • Publication number: 20160106711
    Abstract: Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described.
    Type: Application
    Filed: September 20, 2013
    Publication date: April 21, 2016
    Inventors: José A. HALPERIN, Michael CHOREV, Bertal Huseyin AKTAS
  • Publication number: 20160106712
    Abstract: The invention relates to fatty acid COX inhibitor derivatives; compositions comprising an effective amount of a fatty acid COX inhibitor derivative; and methods for treating or preventing a metabolic, autoimmune inflammatory, or neurodegenerative disorder comprising the administration of an effective amount of a fatty acid COX inhibitor derivative.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20160106713
    Abstract: Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 21, 2016
    Inventors: Sujatha Karoor, Ton That Hai, Cong Jiang, Paul Sanders, Cliff Holmes
  • Publication number: 20160106714
    Abstract: The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 21, 2016
    Inventors: Michael T. Nordsiek, Kolmudi S. Balaji
  • Publication number: 20160106715
    Abstract: A method that inhibits infection during wound healing by topical application of a single composition, which contacts a wound for a period of time to initiate wound healing. The single composition may include a mixture of all or some of the amino acids including: histidine monohydrochloride monohydrate; isoleucine; leucine; lysine acetate; methionine; phenylalanine; threonine; tryptophan; valine; alanine; arginine acetate; aspartic acid; glutamine; glycine; proline; serine; and tyrosine, which may provide aqueous mixtures of a range of osmolarities or a powdered mixture of amino acids. The single composition may also include any of a carbohydrate, a mixture of fatty acids, vitamins, and mineral nutrients, and another mixture of amino acid derivatives and preservatives. The number of moles of the carbohydrate is less than and proportional to a sum of the number of moles of any mixture of amino acids in the single composition.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 21, 2016
    Inventor: John H. Plumb
  • Publication number: 20160106716
    Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
    Type: Application
    Filed: May 20, 2015
    Publication date: April 21, 2016
    Applicant: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
  • Publication number: 20160106717
    Abstract: This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid.
    Type: Application
    Filed: October 15, 2015
    Publication date: April 21, 2016
    Applicant: Gen Pharma Holdings LLC
    Inventor: Sunil Gupta
  • Publication number: 20160106718
    Abstract: This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 21, 2016
    Applicant: Gen Pharma Holdings LLC
    Inventor: Sunil GUPTA